Download PDF
Semin Liver Dis 2017; 37(03): 259-274
DOI: 10.1055/s-0037-1606254
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma

Avinash Kambadakone
1   Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Vinit Baliyan
1   Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Andrew X. Zhu
2   Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
28 August 2017 (online)

    Permissions and Reprints

Abstract

Increasing use of novel systemic treatment options in the management of patients with advanced hepatocellular carcinoma (HCC) such as antiangiogenic and molecular-targeted therapies, poses unique challenges for effective treatment monitoring and efficacy assessment. The traditional morphological criteria such as response evaluation criteria in solid tumor (RECIST) rely on changes in tumor size to determine treatment efficacy. However, these criteria based on tumor morphology may not be suitable to monitor response to newer targeted therapies as early functional changes induced by these drugs precede changes in tumor size. Modifications of these morphological criteria that determine response based on tumor enhancement characteristics such as modified RECIST (mRECIST) will potentially allow improved determination of treatment response pending validation from prospective trials. Advanced functional imaging techniques such as perfusion imaging (computed tomography/magnetic resonance imaging [CT/MRI]), diffusion weighted MRI (DW-MRI) and positron emission tomography (PET/CT and PET/MRI) are being increasingly used as surrogate imaging biomarkers to provide superior assessment of changes in tumor physiology. Growing emphasis on precision oncological care tailored to specific tumor type and individual patients renders the use of these newer imaging modalities more pertinent and timely. In this review, the authors discuss the role of various imaging techniques and response assessment criteria in the evaluation of systemic therapy for advanced HCC with focus on functional imaging tools.

Keywords

hepatocellular carcinoma - computed tomography - magnetic resonance imaging - systemic therapy - response assessment - RECIST - mRECIST
 

  • References

  • 1 Bertuccio P, Turati F, Carioli G. , et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017; S0168-8278(17)30145-9
    PubMedGoogle Scholar
  • 2 Ferlay J, Soerjomataram I, Dikshit R. , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
    CrossrefPubMedGoogle Scholar
  • 3 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol 2013; 5 (06) 311-322
    CrossrefPubMedGoogle Scholar
  • 4 Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2014; 10 (03) 153-161
    PubMedGoogle Scholar
  • 5 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012; 27 (05) 862-872
    CrossrefPubMedGoogle Scholar
  • 6 Llovet JM, Ricci S, Mazzaferro V. , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
    CrossrefPubMedGoogle Scholar
  • 7 Bruix J, Sherman M, Llovet JM. , et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35 (03) 421-430
    CrossrefPubMedGoogle Scholar
  • 8 Cheng A-L, Kang Y-K, Chen Z. , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
    CrossrefPubMedGoogle Scholar
  • 9 Cheng A. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). 2017 ASCO Annual Meeting Abstracts [Internet]. Available at: http://abstracts.asco.org/199/AbstView_199_186143.html . Accessed June 26, 2017
    PubMedGoogle Scholar
  • 10 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48 (04) 1312-1327
    CrossrefPubMedGoogle Scholar
  • 11 Figueiras RG, Padhani AR, Goh VJ. , et al. Novel oncologic drugs: what they do and how they affect images. Radiographics 2011; 31 (07) 2059-2091
    CrossrefPubMedGoogle Scholar
  • 12 Kelley RK, Verslype C, Cohn AL. , et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017; 28 (03) 528-534
    CrossrefPubMedGoogle Scholar
  • 13 Zhu AX, Park JO, Ryoo B-Y. , et al; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015; 16 (07) 859-870
    CrossrefPubMedGoogle Scholar
  • 14 Ikeda K, Kudo M, Kawazoe S. , et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52 (04) 512-519
    CrossrefPubMedGoogle Scholar
  • 15 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 2013; 58 (01) 169-177
    CrossrefPubMedGoogle Scholar
  • 17 Van Beers BE, Daire J-L, Garteiser P. New imaging techniques for liver diseases. J Hepatol 2015; 62 (03) 690-700
    CrossrefPubMedGoogle Scholar
  • 18 Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted?. AJR Am J Roentgenol 2009; 193 (02) 304-313
    CrossrefPubMedGoogle Scholar
  • 19 Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol 2011; 197 (02) W256-9
    PubMedGoogle Scholar
  • 20 Basik M, Aguilar-Mahecha A, Rousseau C. , et al. Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol 2013; 10 (08) 437-450
    CrossrefPubMedGoogle Scholar
  • 21 Eisenhauer EA, Therasse P, Bogaerts J. , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedGoogle Scholar
  • 22 Galizia MS, Töre HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011; 18 (12) 1555-1560
    CrossrefPubMedGoogle Scholar
  • 23 Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014; 34 (04) 444-455
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Horger M, Lauer UM, Schraml C. , et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer [Internet]. Available at: http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-9-208 . Accessed March 26, 2017
    PubMedGoogle Scholar
  • 25 Chun YS, Vauthey J-N, Boonsirikamchai P. , et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302 (21) 2338-2344
    CrossrefPubMedGoogle Scholar
  • 26 Forner A, Ayuso C, Varela M. , et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009; 115 (03) 616-623
    CrossrefPubMedGoogle Scholar
  • 27 Boonsirikamchai P, Asran MA, Maru DM. , et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol 2011; 197 (06) W1060-6
    PubMedGoogle Scholar
  • 28 Bruix J, Sherman M. ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42 (05) 1208-1236
    CrossrefPubMedGoogle Scholar
  • 29 Kudo M, Kubo S, Takayasu K. , et al; Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40 (07) 686-692
    CrossrefPubMedGoogle Scholar
  • 30 Llovet JM, Di Bisceglie AM, Bruix J. , et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10) 698-711
    CrossrefPubMedGoogle Scholar
  • 31 Ronot M, Bouattour M, Wassermann J. , et al. Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; 19 (04) 394-402
    CrossrefPubMedGoogle Scholar
  • 32 Bruix J, Reig M, Sangro B. Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. J Hepatol 2017; 66 (06) 1114-1117
    CrossrefPubMedGoogle Scholar
  • 33 Uchino K, Tateishi R, Shiina S. , et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011; 117 (19) 4475-4483
    CrossrefPubMedGoogle Scholar
  • 34 Lencioni R, Montal R, Torres F. , et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017; 66 (06) 1166-1172
    CrossrefPubMedGoogle Scholar
  • 35 Edeline J, Boucher E, Rolland Y. , et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118 (01) 147-156
    CrossrefPubMedGoogle Scholar
  • 36 Takada J, Hidaka H, Nakazawa T. , et al. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015; 8: 609
    CrossrefPubMedGoogle Scholar
  • 37 Arizumi T, Ueshima K, Takeda H. , et al. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 2014; 49 (12) 1578-1587
    CrossrefPubMedGoogle Scholar
  • 38 Lencioni R, Raoul J-L, Park JW, Baudelet C, Walters I. Comparison of tumor responses by modified WHO and new RECIST criteria from a phase II study of first-line brivanib in hepatocellular carcinoma (HCC). J Clin Oncol [Internet]. Available at: http://meetinglibrary.asco.org/content/1758-72 . Accessed May 3, 2017
    PubMedGoogle Scholar
  • 39 Johnson PJ, Qin S, Park J-W. , et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28) 3517-3524
    CrossrefPubMedGoogle Scholar
  • 40 Bruix J, Qin S, Merle P. , et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10064): 56-66
    CrossrefPubMedGoogle Scholar
  • 41 Meyer T, Palmer DH, Cheng A-L, Hocke J, Loembé A-B, Yen C-J. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017; 37 (07) 1047-1055
    CrossrefPubMedGoogle Scholar
  • 42 Edeline J, Palmer D, Blanc J-F, Campillo-Gimenez B, Merle P, Meyer T. mRECIST for systemic therapies: More evidence is required before recommendations can be made. J Hepatol 2017; 67 (01) 195
    CrossrefPubMedGoogle Scholar
  • 43 Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target?. Clin Cancer Res 2009; 15 (19) 5947-5949
    CrossrefPubMedGoogle Scholar
  • 44 Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010; 30 (06) 591-601
    CrossrefPubMedGoogle Scholar
  • 45 Llovet JM, Decaens T, Raoul J-L. , et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31 (28) 3509-3516
    CrossrefPubMedGoogle Scholar
  • 46 Cheng A-L, Kang Y-K, Lin D-Y. , et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31 (32) 4067-4075
    CrossrefPubMedGoogle Scholar
  • 47 Choi H, Charnsangavej C, de Castro Faria S. , et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183 (06) 1619-1628
    CrossrefPubMedGoogle Scholar
  • 48 Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 49 Gavanier M, Ayav A, Sellal C. , et al. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. Eur J Radiol 2016; 85 (01) 103-112
    CrossrefPubMedGoogle Scholar
  • 50 Ascenti G, Sofia C, Mazziotti S. , et al. Dual-energy CT with iodine quantification in distinguishing between bland and neoplastic portal vein thrombosis in patients with hepatocellular carcinoma. Clin Radiol 2016; 71 (09) 938.e1-938.e9
    CrossrefPubMedGoogle Scholar
  • 51 Qian LJ, Zhu J, Zhuang ZG. , et al. Differentiation of neoplastic from bland macroscopic portal vein thrombi using dual-energy spectral CT imaging: a pilot study. Eur Radiol 2012; 22 (10) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 52 Gordic S, Puippe GD, Krauss B. , et al. Correlation between dual-energy and perfusion CT in patients with hepatocellular carcinoma. Radiology 2016; 280 (01) 78-87
    CrossrefPubMedGoogle Scholar
  • 53 Dai X, Schlemmer H-P, Schmidt B. , et al. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Radiol 2013; 82 (02) 327-334
    CrossrefPubMedGoogle Scholar
  • 54 Lee J-A, Jeong WK, Kim Y. , et al. Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging. Eur J Radiol 2013; 82 (04) 569-576
    CrossrefPubMedGoogle Scholar
  • 55 Thaiss WM, Haberland U, Kaufmann S. , et al. Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using volume perfusion CT with 80 kVp. Eur Radiol 2016; 26 (09) 2929-2936
    CrossrefPubMedGoogle Scholar
  • 56 Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 2009; 47 (01) 161-178
    CrossrefPubMedGoogle Scholar
  • 57 Sahani DV, Holalkere N-S, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 2007; 243 (03) 736-743
    CrossrefPubMedGoogle Scholar
  • 58 Ippolito D, Sironi S, Pozzi M. , et al. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 2008; 15 (07) 919-927
    CrossrefPubMedGoogle Scholar
  • 59 Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13 (02) 120-125
    CrossrefPubMedGoogle Scholar
  • 60 Chen BB, Hsu CY, Yu CW. , et al. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017; 27 (07) 3069-3079
    CrossrefPubMedGoogle Scholar
  • 61 Messiou C, Orton M, Ang JE. , et al. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology 2012; 265 (02) 426-436
    CrossrefPubMedGoogle Scholar
  • 62 Wang Q, Shi G, Wang L, Liu X, Wu R. Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. Br J Radiol 2014; 87 (1035): 20130695
    CrossrefPubMedGoogle Scholar
  • 63 Hsu C-Y, Shen Y-C, Yu C-W. , et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011; 55 (04) 858-865
    CrossrefPubMedGoogle Scholar
  • 64 Lassau N, Koscielny S, Chami L. , et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology 2011; 258 (01) 291-300
    CrossrefPubMedGoogle Scholar
  • 65 Zocco MA, Garcovich M, Lupascu A. , et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol 2013; 59 (05) 1014-1021
    CrossrefPubMedGoogle Scholar
  • 66 Frampas E, Lassau N, Zappa M, Vullierme M-P, Koscielny S, Vilgrain V. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. preliminary results. Eur J Radiol 2013; 82 (05) e205-e211
    CrossrefPubMedGoogle Scholar
  • 67 Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 2003; 45 (03) 169-184
    CrossrefPubMedGoogle Scholar
  • 68 Taouli B, Koh D-M. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254 (01) 47-66
    CrossrefPubMedGoogle Scholar
  • 69 Baliyan V, Das CJ, Sharma R, Gupta AK. Diffusion weighted imaging: Technique and applications. World J Radiol 2016; 8 (09) 785-798
    CrossrefPubMedGoogle Scholar
  • 70 Heijmen L, Ter Voert EEGW, Nagtegaal ID. , et al. Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 2013; 23 (03) 748-756
    CrossrefPubMedGoogle Scholar
  • 71 Galbán CJ, Hoff BA, Chenevert TL, Ross BD. Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed 2017;30(3)
    PubMedGoogle Scholar
  • 72 Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging 2012; 35 (02) 257-279
    CrossrefPubMedGoogle Scholar
  • 73 Anzidei M, Napoli A, Zaccagna F. , et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011; 35 (06) 690-696
    CrossrefPubMedGoogle Scholar
  • 74 Schraml C, Schwenzer NF, Martirosian P. , et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009; 193 (04) W301-7
    PubMedGoogle Scholar
  • 75 Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014; 272 (02) 417-426
    CrossrefPubMedGoogle Scholar
  • 76 Granata V, Fusco R, Catalano O. , et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: the role of intravoxel incoherent motion in diffusion-weighted imaging. PLOS ONE 2015; 10 (11) e0142876
    CrossrefPubMedGoogle Scholar
  • 77 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl. 01) 122S-150S
    CrossrefPubMedGoogle Scholar
  • 78 Hellman RS, Krasnow AZ, Sudakoff GS. Positron emission tomography for staging and assessment of tumor response of hepatic malignancies. Available at: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-2006-939838 . Accessed March 26, 2017
    PubMedGoogle Scholar
  • 79 Ahn SJ, Park M-S, Kim KA. , et al. 18F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One 2013; 8 (08) e71571
    CrossrefPubMedGoogle Scholar
  • 80 Song MJ, Bae SH, Yoo IeR. , et al. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18 (25) 3215-3222
    PubMedGoogle Scholar
  • 81 Salem N, Kuang Y, Corn D. , et al. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol 2011; 13 (01) 140-151
    CrossrefPubMedGoogle Scholar
  • 82 Torizuka T, Tamaki N, Inokuma T. , et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35 (12) 1965-1969
    PubMedGoogle Scholar
  • 83 Kuehl H, Stattaus J, Hertel S. , et al. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours–a single-centre experience. Clin Oncol (R Coll Radiol) 2008; 20 (03) 234-240
    CrossrefPubMedGoogle Scholar
  • 84 Kim BK, Kang WJ, Kim JK. , et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011; 117 (20) 4779-4787
    CrossrefPubMedGoogle Scholar
  • 85 Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics 2009; 29 (06) 1653-1664
    CrossrefPubMedGoogle Scholar
  • 86 Maris JM, Evans AE, McLaughlin AC. , et al. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N Engl J Med 1985; 312 (23) 1500-1505
    CrossrefPubMedGoogle Scholar
  • 87 Li C-W, Kuo YC, Chen C-Y. , et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005; 53 (04) 770-776
    CrossrefPubMedGoogle Scholar
  • 88 Wu B, Peng W-J, Wang P-J. , et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J 2006; 21 (04) 258-264
    PubMedGoogle Scholar
  • 89 Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2011; 35 (02) 167-173
    CrossrefPubMedGoogle Scholar
  • 90 Kuo Y-T, Li C-W, Chen C-Y, Jao J, Wu D-K, Liu G-C. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging 2004; 19 (05) 598-604
    CrossrefPubMedGoogle Scholar
  • 91 Gonzalez-Guindalini FD, Botelho MPF, Harmath CB. , et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 2013; 33 (06) 1781-1800
    CrossrefPubMedGoogle Scholar
  • 92 Pepin KM, Chen J, Glaser KJ. , et al. MR elastography derived shear stiffness--a new imaging biomarker for the assessment of early tumor response to chemotherapy. Magn Reson Med 2014; 71 (05) 1834-1840
    CrossrefPubMedGoogle Scholar
  • 93 Xie M, Zhang X, Jia Z, Ren Y, Wang W. Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma. Oncol Lett 2014; 8 (04) 1652-1656
    CrossrefPubMedGoogle Scholar
  • 94 Kim BK, Kim SU, Kim M-J. , et al. Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 2013; 19 (06) 1503-1511
    CrossrefPubMedGoogle Scholar
  • 95 Bargellini I, Scionti A, Mismas V. , et al. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?. Oncology 2014; 86 (04) 191-198
    CrossrefPubMedGoogle Scholar
  • 96 Welsh JL, Bodeker K, Fallon E, Bhatia SK, Buatti JM, Cullen JJ. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. Am J Surg 2012; 204 (05) 580-585
    CrossrefPubMedGoogle Scholar
  • 97 Sacco R, Faggioni L, Bargellini I. , et al. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Dig Liver Dis 2013; 45 (09) 776-781
    CrossrefPubMedGoogle Scholar